Capecitabine CAS 154361-50-9 Purity 98.0%~102.0% API High Quality
Commercial Supply Capecitabine Related Intermediates:
5-Fluorocytosine CAS: 2022-85-7
2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidine CAS: 161599-46-8
1,2,3-Tri-O-acetyl-5-deoxy-β-D-ribofuranose CAS: 62211-93-2
Capecitabine CAS: 154361-50-9
| Chemical Name | Capecitabine |
| CAS Number | 154361-50-9 |
| CAT Number | RF-API08 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C15H22FN3O6 |
| Molecular Weight | 359.35 |
| Melting Point | 110.0~121.0℃ |
| Shipping Condition | Under Ambient Temperature |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White Powder |
| Identification | IR Spectrum sample should concordant with spectrum of the reference standard |
| Identification | HPLC: The retention time of major peak of the sample solution should correspond to that of reference standard. |
| Purity | 98.0%~102.0% (on the anhydrous and solvent-free basis) |
| Optical Rotation | +96.0°~+100° |
| Moisture (K.F) | ≤0.30% |
| Residue on ignition | ≤0.10% |
| Heavy Metals | ≤20ppm |
| Related Impurity A | ≤0.30% |
| Related Impurity B | ≤0.30% |
| Related Impurity C | ≤0.10% (2',3'-Di O-Acety-5'-deoxy-5-Fluoroytidine) |
| Single Unspecified Impurity | ≤0.10% |
| Total Unspecified Impurities | ≤0.50% |
| Total Impurities | ≤1.5% |
| Residual Solvents (GC) | |
| Methanol | ≤3000ppm |
| Ethanol | ≤5000ppm |
| Dichloromethane | ≤600ppm |
| Ethyl Acetate | ≤5000ppm |
| Toluene | ≤800ppm |
| Pyridine | ≤200ppm |
| Hexane | ≤290ppm |
| Total Aerobic Microbial Count | ≤200cfc/g |
| Yeasts and Molds Count | ≤50cfc/g |
| Test Standard | United States Pharmacopoeia (USP) |
| Usage | Metastatic Breast Cancer |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Capecitabine (CAS: 154361-50-9) is a new form of oral fluorinated pyrimidine drug. Capecitabine was developed by Roche Pharmaceuticals, and its commercial name is Xeloda. Capecitabine can change in vivo into 5- FU, an anti-metabolizim fluorine pyrimidine deoxynucleoside carbamate drug that targets cancer cells to inhibit cell division and disrupt RNA and protein synthesis. Its effects are significantly tied to the level of TP enzyme expression in neoplastic tissue and to DPD enzyme in vivo expression. It is suitable as further treatment for advanced primary or metastatic breast cancer patients who have not responded to paclitaxel or anthracycline antibiotics. As an anticancer drug, it is mostly used to treat advanced primary or metastatic breast cancer, as well as in treatment for non-small cell lung cancer, pancreatic cancer, bladder cancer, rectal cancer, colon cancer, gastric cancer, and other solid tumors.
